Summary of Study ST001108

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000740. The data can be accessed directly via it's Project DOI: 10.21228/M81D57 This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001108
Study TitleNMR Metabolomics of Newborn Heart Tissue Exposed to Excess Maternal Cortisol in Late Gestation - Fetal (part -III)
Study TypeComparison
Study SummarySerum from mothers and fetuses exposed to excess maternal cortisol in late gestation and untreated was compared via NMR metabolomic analysis
University of Florida
DepartmentBiochemsitry & Molecular Biology
Last NameWalejko
First NameJacquelyn
AddressR3-226 Academic Research Building, Department of Biochemistry and Molecular Biology, PO Box 100245, Gainesville, FL 32610-0245
Submit Date2018-12-04
Num Groups2
Total Subjects36
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2019-03-06
Release Version1
Jacquelyn Walejko Jacquelyn Walejko application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000740
Project DOI:doi: 10.21228/M81D57
Project Title:Chronic Maternal Cortisol Excess During Late Gestation Leads to Metabolic Alterations in the Newborn Heart
Project Summary:Our laboratory has previously shown in an ovine model of pregnancy that abnormal elevations in maternal cortisol during late gestation lead to increased fetal cardiac arrhythmias and mortality during peripartum. Furthermore, transcriptomic analysis of the fetal heart suggested alterations in TCA cycle intermediates and lipid metabolites in animals exposed to excess cortisol in utero. Therefore, we utilized a sheep model of pregnancy to determine how chronic increases in maternal cortisol alter maternal and fetal serum prior to birth and neonatal cardiac metabolites and lipids at term. Ewes were either infused with 1 mg/kg/day of cortisol starting at gestational day 115 (n=9), or untreated (n=6). Serum was collected from the mother and fetus (125 d-birth), and hearts were collected following birth. Proton nuclear magnetic resonance (1H-NMR) spectroscopy was conducted to measure metabolic profiles of newborn heart specimens as well as fetal and maternal serum specimens. Mass spectrometry was conducted to measure lipid profiles of newborn heart specimens. We observed alterations in amino acid and TCA cycle metabolism as well as lipid and glycerophospholipid metabolism in newborn hearts after excess maternal cortisol in late gestation. In addition, we observed alterations in amino acid and TCA cycle metabolites in fetal but not in maternal serum during late gestation. These results suggest that fetal exposure to excess maternal cortisol alters placental and fetal metabolism prior to birth and limits normal cardiac metabolic maturation, which may contribute to increased risk of peripartum cardiac arrhythmias observed in these animals, or later life cardiomyopathies.
Institute:University of Florida
Last Name:Keller-Wood
First Name:Maureen
Address:1345 SW Archer Rd, PO 100487, Gainesville, FL, 32610


Subject ID:SU001153
Subject Type:Mammal
Subject Species:Ovis aries
Taxonomy ID:9940
Age Or Age Range:Gestational days 125-birth


Subject type: Mammal; Subject species: Ovis aries (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Source
SA075289F_1616-10_140Control Fetal
SA075290F_753_135Control Fetal
SA075291F_728_144Control Fetal
SA075292F_734_143Control Fetal
SA075293F_728_140Control Fetal
SA075294F_759_138Control Fetal
SA075295F_728_142Control Fetal
SA075296F_767_135Control Fetal
SA075297F_753_130Control Fetal
SA075298F_1618_147Control Fetal
SA075299F_759_142Control Fetal
SA075300F_759_145Control Fetal
SA075301F_734_140Control Fetal
SA075302F_759_130Control Fetal
SA075303F_734_138Control Fetal
SA075304F_1618_144Control Fetal
SA075305F_1618_142Control Fetal
SA075306F_734_142Control Fetal
SA075307F_1618_148Control Fetal
SA075308F_1577_125Control Fetal
SA075309F_753_143Control Fetal
SA075310F_1618_149Control Fetal
SA075311F_1618_145Control Fetal
SA075312F_1618_125Control Fetal
SA075313F_767_130Control Fetal
SA075314F_753_138Control Fetal
SA075315F_767_125Control Fetal
SA075316F_1618_150Control Fetal
SA075317F_1616-10_125Control Fetal
SA075318F_759_144Control Fetal
SA075319F_734_130Control Fetal
SA075320F_734_125Control Fetal
SA075321F_734_144Control Fetal
SA075322F_753_140Control Fetal
SA075323F_1618_130Control Fetal
SA075324F_753_125Control Fetal
SA075325F_759_147Control Fetal
SA075326F_1616-10_137Control Fetal
SA075327F_1618_146Control Fetal
SA075328F_1577_140Control Fetal
SA075329F_1618_138Control Fetal
SA075330F_759_140Control Fetal
SA075331F_1577_138Control Fetal
SA075332F_770_130Control Fetal
SA075333F_1577_120Control Fetal
SA075334F_728_146Control Fetal
SA075335F_1577_130Control Fetal
SA075336F_759_125Control Fetal
SA075337F_770_135Control Fetal
SA075338F_759_146Control Fetal
SA075339F_1616-10_130Control Fetal
SA075340F_1618_143Control Fetal
SA075341F_1618_140Control Fetal
SA075342F_728_135Control Fetal
SA075343F_734_135Control Fetal
SA075344F_728_147Control Fetal
SA075345F_728_130Control Fetal
SA075346F_1618_141Control Fetal
SA075347F_728_138Control Fetal
SA075348F_770_140Control Fetal
SA075349F_1618_135Control Fetal
SA075350F_770_125Control Fetal
SA075351F_770_138Control Fetal
SA075352F_759_135Control Fetal
SA075353F_1577_135Control Fetal
SA075354M_1577_120Control Maternal
SA075355M_1616-10_140Control Maternal
SA075356M_753_125Control Maternal
SA075357M_1618_140Control Maternal
SA075358M_767_138Control Maternal
SA075359M_1577_140Control Maternal
SA075360M_1618_141Control Maternal
SA075361M_1618_135Control Maternal
SA075362M_1618_146Control Maternal
SA075363M_1618_130Control Maternal
SA075364M_1577_130Control Maternal
SA075365M_1577_135Control Maternal
SA075366M_1577_125Control Maternal
SA075367M_1618_144Control Maternal
SA075368M_1616-10_137Control Maternal
SA075369M_753_130Control Maternal
SA075370M_753_138Control Maternal
SA075371M_1577_138Control Maternal
SA075372M_767_130Control Maternal
SA075373M_1616-10_130Control Maternal
SA075374M_1618_138Control Maternal
SA075375M_767_135Control Maternal
SA075376M_759_144Control Maternal
SA075377M_734_144Control Maternal
SA075378M_1618_145Control Maternal
SA075379M_734_135Control Maternal
SA075380M_759_147Control Maternal
SA075381M_728_135Control Maternal
SA075382M_759_145Control Maternal
SA075383M_1618_142Control Maternal
SA075384M_1618_148Control Maternal
SA075385M_728_130Control Maternal
SA075386M_770_138Control Maternal
SA075387M_728_147Control Maternal
SA075388M_759_135Control Maternal
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 178


Collection ID:CO001147
Collection Summary:Blood samples were collected from ewe and fetus on gestational days 125, 130, 135, 138, 140, and every subsequent day until birth (control: 144±1; CORT: 142±2 days gestational age);
Sample Type:Blood (serum)
Collection Method:samples for metabolomics analysis were collected in glass tubes on ice with no anticoagulant and spun for 20 min at 4 °C; the resulting serum was stored at -20 °C until metabolomic analysis.
Collection Location:University of Florida
Storage Conditions:-20℃
Collection Vials:Eppendorf tubes
Storage Vials:Eppendorf tubes


Treatment ID:TR001167
Treatment Summary:The treatment protocol for this study was previous published in Antolic, A., et al. (2018). Chronic maternal hypercortisolemia in late gestation alters fetal cardiac function at birth. Am J Physiol Regul Integr Comp Physiol 314(3): R342-R352.
Treatment Compound:Hydrocortisone sodium succinate in sodium phosphate (Solu-Cortef; Pfizer, New York, NY, USA)
Treatment Dose:1 mg/kg/day

Sample Preparation:

Sampleprep ID:SP001160
Sampleprep Summary:Saline buffer was created by weighing 9 g of NaCl into a 1 L volumetric flask. Next, 100 mL of D2O was added and filled up to 1 L with water and shaken until dissolved. Samples were thawed on ice and centrifuged at 3,000 g for 20 min at 4 °C. Two hundred mL of serum was mixed with 400 mL of Saline buffer and centrifuged for 10 min at 3000 g at 4 °C. For each sample, 500 mL of the resulting supernatant was transferred into a 5 mm SampleJet NMR tube (Bruker Biospin, Billerica, MA, USA).


Analysis ID:AN001802
Laboratory Name:Advanced Magnetic Resonance Imaging and Spectroscopy Facility-University of Florida
Analysis Type:NMR
Analysis Protocol
Acquisition Parameters
Software Version:Topspin 3.6
Operator Name:Jacquelyn Walejko
Processing Parameters
Num Factors:4
Num Metabolites:38
Units:Area under curve


NMR ID:NM000138
Analysis ID:AN001802
Instrument Name:Bruker Avance III
Instrument Type:FT-NMR
NMR Experiment Type:1D 1H
Field Frequency Lock:H2O+D2O
Spectrometer Frequency:600 MHz
NMR Probe:5mm Cryoprobe
NMR Solvent:D2O
NMR Tube Size:5mm
Shimming Method:Topshim
Pulse Sequence:cpmgpr1d
Water Suppression:Presaturation
Power Level:7.37 W
Receiver Gain:64
Offset Frequency:2824.2
Presaturation Power Level:6.41E-05
Number Of Scans:128
Dummy Scans:16
Acquisition Time:1.8173
Relaxation Delay:4 sec
Spectral Width:15.0182 ppm
Num Data Points Acquired:32764
Real Data Points:65536
Line Broadening:1